- Home
- EVF vs CRDF Comparison
EVF vs CRDF Comparison
Compare EVF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- CRDF
- Stock Information
- Founded
- EVF 1998
- CRDF 1999
- Country
- EVF United States
- CRDF United States
- Employees
- EVF N/A
- CRDF N/A
- Industry
- EVF Investment Managers
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVF Finance
- CRDF Health Care
- Exchange
- EVF Nasdaq
- CRDF Nasdaq
- Market Cap
- EVF 112.0M
- CRDF 134.0M
- IPO Year
- EVF N/A
- CRDF N/A
- Fundamental
- Price
- EVF $6.24
- CRDF $2.50
- Analyst Decision
- EVF
- CRDF Strong Buy
- Analyst Count
- EVF 0
- CRDF 3
- Target Price
- EVF N/A
- CRDF $9.33
- AVG Volume (30 Days)
- EVF 93.3K
- CRDF 1.1M
- Earning Date
- EVF 01-01-0001
- CRDF 11-07-2024
- Dividend Yield
- EVF 10.68%
- CRDF N/A
- EPS Growth
- EVF N/A
- CRDF N/A
- EPS
- EVF 0.94
- CRDF N/A
- Revenue
- EVF N/A
- CRDF $688,000.00
- Revenue This Year
- EVF N/A
- CRDF $15.00
- Revenue Next Year
- EVF N/A
- CRDF N/A
- P/E Ratio
- EVF $6.74
- CRDF N/A
- Revenue Growth
- EVF N/A
- CRDF 49.57
- 52 Week Low
- EVF $5.20
- CRDF $1.15
- 52 Week High
- EVF $6.84
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- EVF 50.18
- CRDF 40.06
- Support Level
- EVF $6.21
- CRDF $2.85
- Resistance Level
- EVF $6.26
- CRDF $2.70
- Average True Range (ATR)
- EVF 0.05
- CRDF 0.42
- MACD
- EVF -0.00
- CRDF -0.12
- Stochastic Oscillator
- EVF 45.45
- CRDF 1.83
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").